Literature DB >> 16604300

RGS4 genotype is not associated with antipsychotic medication response in schizophrenia.

O Kampman1, A Illi, K Hänninen, H Katila, S Anttila, R Rontu, K M Mattila, E Leinonen, T Lehtimäki.   

Abstract

The aims of the present study were to compare the allele frequencies of a common single nucleotide polymorphism located upstream of the regulator of G-protein signaling 4 (RGS4) gene (T > G, Rs 951436) in 219 Finnish patients with schizophrenia and in 389 control subjects, to analyze corresponding frequencies between two different subtypes of 93 schizophrenia patients according to their medication response, and to study the effect of this SNP on age at onset in schizophrenia. The RGS4 (T > G, Rs 951436) genotype was not associated with incidence or age at onset in schizophrenia. Neither was the RGS4 genotype associated with medication response with two different subpopulations with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16604300     DOI: 10.1007/s00702-006-0445-2

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  23 in total

1.  Support for RGS4 as a susceptibility gene for schizophrenia.

Authors:  Nigel M Williams; Anna Preece; Gillian Spurlock; Nadine Norton; Hywel J Williams; Robin G McCreadie; Paul Buckland; Val Sharkey; Kodavali V Chowdari; Stanley Zammit; Vishwajit Nimgaonkar; George Kirov; Michael J Owen; Michael C O'Donovan
Journal:  Biol Psychiatry       Date:  2004-01-15       Impact factor: 13.382

Review 2.  Regulators of G-protein signalling as new central nervous system drug targets.

Authors:  Richard R Neubig; David P Siderovski
Journal:  Nat Rev Drug Discov       Date:  2002-03       Impact factor: 84.694

3.  Dopamine receptor-mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time.

Authors:  Jean-Marc Taymans; Hossein Kami Kia; Robby Claes; Catarina Cruz; Josée Leysen; Xavier Langlois
Journal:  Eur J Neurosci       Date:  2004-04       Impact factor: 3.386

4.  Failure to confirm association between RGS4 haplotypes and schizophrenia in Caucasians.

Authors:  Janet L Sobell; Christian Richard; Donna A Wirshing; Leonard L Heston
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

5.  Association and linkage analyses of RGS4 polymorphisms in schizophrenia.

Authors:  Kodavali V Chowdari; Karoly Mirnics; Prachi Semwal; Joel Wood; Elizabeth Lawrence; Triptish Bhatia; Smita N Deshpande; Thelma B K; Robert E Ferrell; Frank A Middleton; Bernie Devlin; Pat Levitt; David A Lewis; Vishwajit L Nimgaonkar
Journal:  Hum Mol Genet       Date:  2002-06-01       Impact factor: 6.150

6.  Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions.

Authors:  Jean-Marc Taymans; Josée E Leysen; Xavier Langlois
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

7.  Regulator of G-protein signaling 4 (RGS4) gene is associated with schizophrenia in Irish high density families.

Authors:  Xiangning Chen; Cynthia Dunham; Seth Kendler; Xu Wang; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2004-08-15       Impact factor: 3.568

8.  Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity.

Authors:  Afshin Ghavami; Rachel A Hunt; Michael A Olsen; Jie Zhang; Deborah L Smith; Sachin Kalgaonkar; Zia Rahman; Kathleen H Young
Journal:  Cell Signal       Date:  2004-06       Impact factor: 4.315

9.  Confirming RGS4 as a susceptibility gene for schizophrenia.

Authors:  Derek W Morris; Alana Rodgers; Kevin A McGhee; Siobhan Schwaiger; Paul Scully; John Quinn; David Meagher; John L Waddington; Michael Gill; Aiden P Corvin
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2004-02-15       Impact factor: 3.568

10.  Regional expression of RGS4 mRNA in human brain.

Authors:  Holly A Erdely; Robert A Lahti; Mary B Lopez; Carol S Myers; Rosalinda C Roberts; Carol A Tamminga; Michael W Vogel
Journal:  Eur J Neurosci       Date:  2004-06       Impact factor: 3.386

View more
  6 in total

Review 1.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

2.  Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment.

Authors:  G Rivero; A M Gabilondo; J A García-Sevilla; L F Callado; R La Harpe; B Morentin; J J Meana
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

3.  Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

Authors:  Daniel B Campbell; Philip J Ebert; Tara Skelly; T Scott Stroup; Jeffrey Lieberman; Pat Levitt; Patrick F Sullivan
Journal:  Biol Psychiatry       Date:  2007-06-22       Impact factor: 13.382

4.  Association of RGS2 and RGS5 variants with schizophrenia symptom severity.

Authors:  Daniel B Campbell; Leslie A Lange; Tara Skelly; Jeffrey Lieberman; Pat Levitt; Patrick F Sullivan
Journal:  Schizophr Res       Date:  2008-02-11       Impact factor: 4.939

Review 5.  Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.

Authors:  Amy L Gillespie; Ruta Samanaite; Jonathan Mill; Alice Egerton; James H MacCabe
Journal:  BMC Psychiatry       Date:  2017-01-13       Impact factor: 3.630

6.  Association between RGS4 gene polymorphisms and schizophrenia: A protocol for systematic review and meta-analysis.

Authors:  Feng-Ling Xu; Jun Yao; Bao-Jie Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-05       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.